Dickson, M. A., Ravi, V., Riedel, R. F., Ganjoo, K. N., Van Tine, B. A., Chugh, R., … Wagner, A. J. (2022). nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Dickson, Mark Andrew, Vinod Ravi, Richard F. Riedel, Kristen N. Ganjoo, Brian Andrew Van Tine, Rashmi Chugh, Lee D. Cranmer, et al. “nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Dickson MA, Ravi V, Riedel RF, Ganjoo KN, Van Tine BA, Chugh R, et al. nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Dickson, Mark Andrew, et al. “nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Dickson MA, Ravi V, Riedel RF, Ganjoo KN, Van Tine BA, Chugh R, Cranmer LD, Gordon EM, Chen JL, Murphy MC, Schmid AN, Desai N, Palma NA, Kwiatkowski DJ, Wagner AJ. nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program. JOURNAL OF CLINICAL ONCOLOGY. 2022.